Hold the Presses is your online newsportal en brings press releases from around the world. Journalists can use it for free, although it is their responsibilty to check the news. Hold the Presses is in no way responsible for the content of the press releases, the Sender is. We hope you enjoy reading the news we bring you on this website. If a message is published that is not acceptable, we apologize. Please contact us and we will remove the message as soon as possible.

Friday, 13 October 2017

Summit Therapeutics plc : Holding(s) in Company

     

Published: 10:10 CEST 13-10-2017 /GlobeNewswire /Source: Summit Therapeutics plc / : SUMM /ISIN: GB00BN40HZ01

Summit Therapeutics plc : Holding(s) in Company

TR-1: Standard form for notification of major holdings

 

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

Summit Therapeutics PLC

Sedol BN40HZ0

1b. Please indicate if the issuer is a non-UK issuer  (please mark with an "X" if appropriate)

Non-UK issuer

 

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

 

An acquisition or disposal of financial instruments

 

An event changing the breakdown of voting rights

X

Other (please specify)iii:

 

3. Details of person subject to the notification obligationiv

Name

1Lansdowne Partners International Limited

2Lansdowne Partners Limited

3Lansdowne Partners (UK) LLP

City and country of registered office (if applicable)

London, United Kingdom

4. Full name of shareholder(s) (if different from 3.)v

Name

 

HSBC Client Holdings Nominee (UK) Ltd

HSBC Bank Plc Lansdowne Markets

Morgan Stanley Client Securities Nominees Limited

 

(Registered Shareholders)

 

City and country of registered office (if applicable)

N/A

5. Date on which the threshold was crossed or reachedvi:

11/10/2017

6. Date on which issuer notified (DD/MM/YYYY):

12/10/2017

7. Total positions of person(s) subject to the notification obligation

 

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments
(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights of issuervii

Resulting situation on the date on which threshold was crossed or reached

15.68%

11.30%

26.99%

70,629,352

Position of previous notification (if

applicable)

15.75%

11.35%

27.11%

 

 


8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type of
shares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

GB00BN40HZ01

 

11,077,170

 

15.68%

 

 

 

 

 

 

 

 

 

 

SUBTOTAL 8. A

11,077,170

15.68%

 

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expiration
date
x

Exercise/
Conversion Period
xi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

American Depositary Shares (ADS)

N/A

N/A

7,983,330

11.30%

 

 

SUBTOTAL 8. B 1

7,983,330

11.30%

 

 

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expiration
date
x

Exercise/
Conversion Period
xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

SUBTOTAL 8.B.2

 

 

 

 

 

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

 

Full chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held starting with the ultimate controlling natural person or legal entity
xiv (please add additional rows as necessary)

X

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

Lansdowne Partners

International Limited

15.68%

11.30%

26.99%

Lansdowne Partners

Limited

 

 

 

Lansdowne Partners (UK) LLP

15.68%

11.30%

26.99%

 

10. In case of proxy voting, please identify:

Name of the proxy holder

 

The number and % of voting rights held

 

The date until which the voting rights will be held

 

 

11. Additional informationxvi

 

 

Place of completion

London

Date of completion

12 October 2017

 





This announcement is distributed by Nasdaq Corporate Solutions (One Liberty Plaza, 165 Broadway, New York, NY 10006. Tel: +1 212 401 8700. www.nasdaqomx.com) on behalf of Nasdaq Corporate Solutions clients. Source: Summit Therapeutics plc, 85b Park Drive Milton Park, Abingdon OX14 4RY,, United Kingdom
If you would like to unsubscribe and stop receiving these e-mails click here.